EUVIMEDEUVIMED entdecken
Fallbericht

Utilizing plasma drug levels and genetic testing to achieve optimal treatment response in a patient with treatment‐resistant schizoaffective disorder

Jin-Jie Xu iD, Chunfeng Xiao, Yanli Pan, Yi-Lang Tang, Mingwan Wang, Sheng Li, Gaoming Xie, Jing Du, Yanping Ren, Wei Wang

Bipolar Disorders · 2024

DOI: 10.1111/bdi.13385 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Bipolar Disorders, 2024. Verfasst von Jin-Jie Xu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Beijing Key Laboratory of Mental Disorders, National Clinical Research Center for Mental Disorders & National Center for Mental Disorders, Beijing An…. Hauptthemen laut MEDLINE: Clozapine, Antipsychotic Agents, Bipolar Disorder, Psychotic Disorders. Die Arbeit nennt 5 Literaturangaben. Gefördert von: Beijing Municipal Administration of Hospitals Incubating Program, the Scientific Research Fund of Beijing Anding Hospital.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We report the case of a Chinese male with schizoaffective disorder, an active smoker and a nonresponder to clozapine (600 mg daily). Therapeutic clozapine monitoring was analyzed, revealing a low concentration‐dose ratio. A pharmacogenetic test showed that the patient had the CYP1A2*1F/*1F genotype, indicating an ultra‐rapid clozapine metabolizer. In combination with fluvoxamine, a CYP1A2 enzyme inhibitor, clozapine plasma concentrations approached the reference range and achieved clinical improvement. This case demonstrates how pharmacogenetics can help understand the value of therapeutic drug monitoring to enhance the treatment of refractory schizoaffective disorder.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ClozapineAntipsychotic AgentsBipolar DisorderPsychotic DisordersMaleHumansCytochrome P-450 CYP1A2Genetic Testing

Stichwörter der Autor:innen

clozapinepharmacogenomicsschizoaffective disordertherapeutic drug monitoringtreatment-resistant

Substanzen

ClozapineCytochrome P-450 CYP1A2Antipsychotic Agents

Autor:innen und Institutionen

  • Beijing Key Laboratory of Mental Disorders, National Clinical Research Center for Mental Disorders & National Center for Mental Disorders, Beijing Anding Hospital, Capital Medical University, Beijing, China.
  • Advanced Innovation Center for Human Brain Protection, Capital Medical University, Beijing, China.
  • Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
  • Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, Georgia, USA.
  • Mental Health Service Line, Joseph Maxwell Cleland Atlanta VA Medical Center, Decatur, Georgia, USA.

ORCID-Profile: Jin-Jie Xu

Förderung

  • Beijing Municipal Administration of Hospitals Incubating Program
  • the Scientific Research Fund of Beijing Anding Hospital

Zitieren

APA

Xu, J. J., Xiao, C., Pan, Y., Tang, Y. L., Wang, M., Li, S., Xie, G., Du, J., Ren, Y., & Wang, W. (2024). Utilizing plasma drug levels and genetic testing to achieve optimal treatment response in a patient with treatment‐resistant schizoaffective disorder. Bipolar Disorders. https://doi.org/10.1111/bdi.13385

Vancouver

Xu JJ, Xiao C, Pan Y, Tang YL, Wang M, Li S, et al. Utilizing plasma drug levels and genetic testing to achieve optimal treatment response in a patient with treatment‐resistant schizoaffective disorder. Bipolar Disorders. 2024. doi:10.1111/bdi.13385

BibTeX
@article{Xu2024,
  author = {Xu, Jin-Jie and Xiao, Chunfeng and Pan, Yanli and Tang, Yi-Lang and Wang, Mingwan and Li, Sheng and Xie, Gaoming and Du, Jing and Ren, Yanping and Wang, Wei},
  title = {Utilizing plasma drug levels and genetic testing to achieve optimal treatment response in a patient with treatment‐resistant schizoaffective disorder},
  journal = {Bipolar Disorders},
  year = {2024},
  doi = {10.1111/bdi.13385}
}
Kostenlos starten →